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Background and Objective: Atrial fibrillation (AF), the most common cardiac arrhythmia,
typically increases with age. Oral anticoagulants (OACs) are the cornerstone of treatment to
reduce the associated risk for systemic thromboembolism. Four large randomized
controlled trials (RCTs) have shown that non-vitamin K antagonist oral anticoagulants
(NOACs) are non-inferior to vitamin K antagonists (VKAs) in preventing stroke and systemic
embolism, as well as regarding their risk for major bleeding. However, as vulnerable geriatric
patients with AF were largely underrepresented in these trials, physicians are faced with the
challenge of choosing the right anticoagulant for geriatric patients in real-life clinical practice.
In this vulnerable patient group, NOACs tend to be underused or underdosed due to
concerns of excessive fall-related intracranial bleeding, cognitive impairment, multiple drug-
drug interactions, low body weight or impaired renal function. As life expectancy continues
to rise worldwide, the number of geriatric patients substantially increases. Therefore, there is
an urgent need for a critical appraisal of the added value of NOACs in geriatric patients with
AF at high thromboembolic and bleeding risk.
Methods and Results: This systematic review provides an overview of the literature on
the impact of increased age (≥75 years), multimorbidity, polypharmacy, increased falling
risk, frailty and dementia on the effectiveness and safety of NOACs as compared to VKAs,
after searching the Medline database. Moreover, a meta-analysis on the impact of
increased age ≥75 years old was performed after pooling results from 6 post hoc
analyses of RCTs and 6 longitudinal observational cohort studies, highlighting the
superior effectiveness (hazard ratio (HR) 0.83, 95% confidence interval (CI) [0.74–0.94]
for stroke/SE; HR 0.77, 95%CI [0.65–0.92] for mortality) and non-inferior safety (HR 0.93,
95%CI [0.86–1.01] for major bleeding; HR 0.58, 95%CI [0.50–0.67] for intracranial
bleeding; HR 1.17, 95%CI [0.99–1.38] for gastrointestinal bleeding) of NOACs versus
VKAs in older AF patients.in.org September 2020 | Volume 11 | Article 5833111
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Frontiers in Pharmacology | www.frontiersConclusion: Across geriatric subgroups, apixaban was consistently associated with the
most favourable benefit-risk profile and should therefore be preferred in geriatric patients
with AF. However, research gaps on the impact of increased falling risk, frailty and baseline
dementia were identified, requiring careful consideration while awaiting more results.Keywords: atrial fibrillation, oral anticoagulant, increased age, multimorbidity, polypharmacy, fall, frailty, dementiaINTRODUCTION
As life expectancy continues to rise worldwide, the number of
geriatric patients substantially increases (Beard et al., 2016). In
older patients ≥75 years old, multimorbidity, polypharmacy,
recurring falling incidents, frailty and dementia tend to rise in
prevalence and tend to coincide (Jaspers Focks et al., 2016; Piccini
et al., 2016; Steffel et al., 2016; Rao et al., 2018; Martinez et al., 2018;
Alexander et al., 2019). Although high age, frequently defined in
studies as ≥75 years, is not a de facto criterion for a geriatric
profile, it has been independently associated with higher risks of
systemic thromboembolism, major bleeding, intracranial bleeding
and mortality (Wolf et al., 1991; Oldgren et al., 2011; Halvorsen
et al., 2014; Kato et al., 2016; Chao et al., 2020; Kirchhof et al.,
2020). Moreover, the incidence and prevalence of atrial fibrillation
(AF), the most frequent cardiac arrhythmia worldwide, typically
increases with age (Heeringa et al., 2006; Lee et al., 2017). Oral
anticoagulants (OACs) are crucial to reduce the associated risk of
systemic thromboembolism in non-valvular AF (hereby
referenced as AF) (Steffel et al., 2018). Four large phase III
randomized controlled trials (RCTs) (RE-LY trial for dabigatran
(Connolly et al., 2009), ROCKET AF trial for rivaroxaban (Patel
et al., 2011), ARISTOTLE trial for apixaban (Granger et al., 2011),
ENGAGE AF-TIMI 48 trial for edoxaban (Giugliano et al., 2013))
have shown that non-vitamin K antagonist oral anticoagulants
(NOACs) are at least non-inferior for stroke prevention and for
the risk of bleeding events as compared to vitamin K antagonists
(VKAs) (Connolly et al., 2009; Patel et al., 2011; Granger et al.,
2011; Giugliano et al., 2013; Ruff et al., 2014). However, concerns
have risen regarding the effectiveness and safety of NOACs in real-
life clinical practice in patients with multiple comorbidities and
concomitant medication use, especially vulnerable geriatric
patients with AF who were largely underrepresented in these
trials (Lee et al., 2012). Consequently, NOACs tend to be
underused or underdosed in these patients due to concerns of
excessive fall-related intracranial bleeding, cognitive impairment
with suboptimal therapy adherence, multiple drug-drug
interactions (DDIs), low body weight or impaired renal function
(Viscogliosi et al., 2017; Oqab et al., 2018; Proietti et al., 2019;
Madhavan et al., 2019; Besford et al., 2020; Kapoor et al., 2020;
Sanghai et al., 2020). Therefore, there is an urgent need for a
critical appraisal of the added value of NOACs in geriatric patients
with AF at high thromboembolic and bleeding risk.
This systematic review will provide an overview of the literature
on the impact of increased age (≥75 years), multimorbidity,
polypharmacy (≥5 drugs) (Masnoon et al., 2017), high falling
risk, frailty and dementia on the effectiveness and safety of
NOACs versus VKAs in geriatric patients with AF. Moreover, ain.org 2meta-analysis on the impact of increased age ≥75 years old on
NOAC versus VKA effectiveness and safety will be performed.
Thereby, this overview will help guide physicians in their OAC
choice for vulnerable older patients with AF.METHODS
A thorough literature search was performed using the Medline
database by one reviewer (MG) (see supplemental materials,
eTable 1). Articles related to oral anticoagulant use for stroke
prevention in adult patients with non-valvular AF and increased
age (≥75 years), multimorbidity, polypharmacy (≥5 drugs), high
falling risk, frailty and baseline dementia were selected. Only studies
longitudinally comparing the effectiveness and safety of NOACs
(dabigatran, rivaroxaban, apixaban and/or edoxaban) compared to
VKAs (warfarin, phenprocoumon and/or acenocoumarol) during a
mean/median follow-up of at least 3 months in these patient
subgroups were included. Studies regarding OAC use for non-AF
indications (e.g. venous thromboembolisms or mechanic heart
valves) were excluded if no separate results of patients with AF
were provided. Effectiveness and safety outcomes of interest were
stroke or systemic embolism (stroke/SE), major bleeding (overall,
intracranial and/or gastrointestinal) and all-cause mortality. RCTs
(original trial or post hoc analyses), longitudinal observational
cohort studies and meta-analyses written in English were included
for a qualitative synthesis, while reviews, cross-sectional studies, case
reports, editorials or conference proceedings were left out of
consideration. For a quantitative synthesis (meta-analysis), only
post hoc analyses of RCTs and longitudinal observational cohort
studies regarding the impact of increased age ≥75 years old on
NOAC versus VKA effectiveness (stroke/SE, mortality) and safety
(major, intracranial and gastrointestinal bleeding) were included.
Studies including even older AF patients (e.g. ≥80, 85, or 90 years
old) were not included in the meta-analysis, due to concerns of
channelling bias (Alcusky et al., 2020) in the introduction years and
selective prescribing (of NOACs to more comorbid patients) later
on, andmore frequent inappropriate NOAC dosing in observational
studies (Shinohara et al., 2019; Raposeiras-Roubıń et al., 2020) in
the oldest AF patients. However, these results were included in an
additional subgroup analysis. No restriction of publication date
was used.
On April 24, 2020, 4358 articles were identified. Additional
articles of interest were identified by screening the reference list
of studies. After screening title and abstract, 80 articles were
selected by one reviewer. After reading the full-text, 50 articles
were selected for the qualitative synthesis and 12 for a
quantitative synthesis (i.e. 6 post hoc analyses of RCTs, 6September 2020 | Volume 11 | Article 583311
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studies with study design, patient characteristics and outcome
measures are displayed in tables (eTables 2–7).
For the impact of increased age ≥75 years old, a meta-analysis
was performed using a random effects model with inverse-variance
weighting with the metafor package in R (R version 3.6.1 with
RStudio version 1.2.5001), by pooling results based on the
logarithmic adjusted hazard ratios (HRs) and standard error.
Data on the study characteristics (design, setting and duration),
baseline characteristics of included patients (total number and age),
intervention (e.g. NOAC versus VKA) and the abovementioned
effectiveness and safety outcomes of interest were extracted fromFrontiers in Pharmacology | www.frontiersin.org 3the original publications or supplemental materials. Effect sizes
were presented as HR with 95% confidence interval (95%CI) for
the outcome of interest of NOAC versus VKA users in forest
plots using the forestplot package in R. A two-sided p-value of <0.05
was considered statistically significant. Heterogeneity was tested
using the I²-statistic and Cochran’s Q-test, based on a restricted
maximum-likelihood estimator. To assess the risk of bias of each
study included in the meta-analysis, the quality assessment tool
“QUALSYST” from the “Standard Quality Assessment Criteria for
Evaluating Primary Research Papers from a Variety of Fields” was
used (eTable 8) (Kmet et al., 2004). With this tool, 14 items of each
quantitative study were scored on the study and outcome levelsFIGURE 1 | PRISMA flow diagram.September 2020 | Volume 11 | Article 583311
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reported (“yes” = 2, “partial” = 1, “no” = 0). Items not applicable to
a particular study design were marked “n/a” and were excluded
from the calculation of the summary score. A percentage was
calculated for each paper by dividing the total sum score obtained
across rated items by the total possible score. Studies were included
if scoring at least 80% on the quality assessment tool. The risk of
publication bias at the outcome level for the studies included in the
meta-analysis was assessed through funnel plot asymmetry and
Egger’s regression test. This work has been performed according to
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (PRISMA checklist included in
supplemental materials, eTable 9).RESULTS
Increased Age
Randomized Studies
Several post hoc analyses and meta-analyses of the pivotal phase
III RCTs have been performed, illustrating similar stroke/SE and
mortality risks with reduced dose NOACs in AF patients ≥75
years old as compared to warfarin, whereas significantly lower
stroke/SE and mortality risks with standard dose NOACs were
observed (eTable 2) (Ruff et al., 2014; Sadlon and Tsakiris, 2016;
Kim et al., 2018; Caldeira et al., 2019; Malik et al., 2019).
Furthermore, besides a significantly lower intracranial
bleeding risk and a similar major bleeding risk for both
standard and reduced dose NOACs (Ruff et al., 2014; Sadlon
and Tsakiris, 2016; Kim et al., 2018; Caldeira et al., 2019; Malik
et al., 2019), a similar to significantly higher gastrointestinal
bleeding risk for reduced and standard dose NOACs
respectively has been illustrated (Kim et al., 2018; Malik et al.,
2019). However, substantial heterogeneity was detected in these
meta-analyses for the bleeding risk assessment in older patients
(I²-value ranging from 84% (Malik et al., 2019) to 94%) (Kim
et al., 2018), potentially attributed to differences in the safety
profile of individual NOACs (Sadlon and Tsakiris, 2016; Kim
et al., 2018; Caldeira et al., 2019; Malik et al., 2019). Indeed, in
the individual post hoc analyses of RCTs, an increased
bleeding risk for dabigatran and rivaroxaban was observed in
older AF patients, as opposed to lower risks for apixaban
and edoxaban.
In a subgroup analysis of the RE-LY trial, a significant interaction
between age and treatment for major and gastrointestinal bleeding
was seen for dabigatran (Eikelboom et al., 2011). In AF patients ≥75
years old, similar major bleeding and significantly higher
gastrointestinal bleeding risks were seen for both dabigatran doses
(Eikelboom et al., 2011). In AF patients 80–84 years old, significantly
higher major bleeding and major extracranial bleeding risks, and a
similar intracranial bleeding risk was observed for standard dose
dabigatran (150 mg), whereas a significantly lower intracranial
bleeding, similar major bleeding and significantly higher
extracranial bleeding risk was noted for reduced dose dabigatran
(110 mg) as compared to warfarin (Lauw et al., 2017). The point of
reversal from lower to higher major bleeding rates along the ageFrontiers in Pharmacology | www.frontiersin.org 4spectrum was estimated to be >77 years for dabigatran 150 mg and
>80 years for dabigatran 110 mg. For extracranial major bleeding,
this reversal point was >74 years and >76 years respectively. Based
on these results, an age of 75–80 years was implemented as a
criterion to consider dose reduction and ≥80 years of age was
implemented as a dose reduction criterion for dabigatran
(Boehringer Ingelheim, 2010; Eikelboom et al., 2011). Nonetheless,
these results illustrate the potentially worse safety outcomes for
dabigatran in older patients, especially regarding the gastrointestinal
bleeding risk. Moreover, worse safety outcomes have been observed
for rivaroxaban in AF patients ≥75 years old, as a post hoc analysis of
the ROCKET AF trial documented significantly higher
gastrointestinal bleeding risks, whereas similar major bleeding and
intracranial bleeding risks for rivaroxaban as compared to warfarin
were noted (Halperin et al., 2014). Similarly, in the Japanese J-
ROCKET AF trial, rivaroxaban use in older AF patients was
associated with a similar major bleeding risk (Hori et al., 2014).
On the contrary, apixaban use has been associated with a
significantly lower major bleeding, intracranial bleeding and major
bleeding risk as compared to warfarin in AF patients ≥75 years old
in a subgroup analysis of the ARISTOTLE trial (no report of
gastrointestinal bleeding risk) (Halvorsen et al., 2014). Even in an
exploratory analysis among AF patients ≥80 years old, superior
safety results were observed. Likewise, edoxaban use in AF patients
≥75 years old was associated with a similar (standard dose
edoxaban) to significantly lower (reduced dose edoxaban) major
bleeding risk and a significantly lower intracranial bleeding risk as
compared to warfarin in a post hoc analysis of the ENGAGE AF-
TIMI 48 trial, although a significantly higher gastrointestinal
bleeding risk was observed (Kato et al., 2016). Results were
consistent in patients ≥80 and ≥85 years old.
Based on the abovementioned results, network meta-analyses
have specifically compared the efficacy and safety of NOACs in
AF patients ≥75 years old (Lin et al., 2015; Sadlon and Tsakiris,
2016; Malik et al., 2019; Deng et al., 2020). Despite a similar
stroke/SE risk (Lin et al., 2015; Sadlon and Tsakiris, 2016; Malik
et al., 2019), these indirect head-to-head comparisons between
NOACs have highlighted significantly lower major bleeding risks
for apixaban and edoxaban as compared to dabigatran (both
doses) and rivaroxaban, except for a similar risk between
edoxaban and dabigatran 110 mg (Lin et al., 2015; Sadlon and
Tsakiris, 2016; Malik et al., 2019). No significant differences in
major bleeding were observed when indirectly comparing
apixaban to edoxaban, and dabigatran to rivaroxaban (Lin
et al., 2015; Malik et al., 2019). Importantly, rivaroxaban was
associated with a significantly higher risk for intracranial
bleeding as compared to other NOACs (Lin et al., 2015; Malik
et al., 2019). Moreover, a network meta-analysis that estimated
the rank probability of OACs in AF patients ≥75 years old, which
reflects the hierarchy of drugs on efficacy and safety, showed that
apixaban ranked best on both stroke/SE prophylaxis (followed by
rivaroxaban, edoxaban, dabigatran 110 mg and warfarin) and
major bleeding risk (followed by edoxaban, dabigatran 110 mg,
warfarin, and rivaroxaban) (Deng et al., 2020). In another
network meta-analysis, although dabigatran 150 mg ranked
best on efficacy outcomes followed by apixaban, apixaban alsoSeptember 2020 | Volume 11 | Article 583311
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worst (Malik et al., 2019).
In conclusion, these post hoc analyses and meta-analyses of
RCTs have shown that apixaban is associated with the best
efficacy and safety profile of all OACs in older AF patients,
followed by edoxaban (Lin et al., 2015; Sadlon and Tsakiris, 2016;
Malik et al., 2019; Deng et al., 2020).Observational Studies
As older AF patients included in RCTs may have been relatively
less comorbid and more compliant, there are concerns regarding the
extrapolation of these results to real-life clinical practice. Moreover,
the number of very old patients (≥85 years old) was limited in these
RCTs. Therefore, post-surveillance observational studies are equally
important in the evaluation of the effectiveness and safety of NOACs
in older AF patients. Several have been performed in different age
strata, however, mostly without edoxaban data, and have described
comparable results as the randomized studies, illustrating the non-
inferior to superior effectiveness and safety of NOACs over VKAs,
the benefit of OAC continuation over discontinuation and the
superior safety profile of apixaban (eTable 2).
In terms of effectiveness, NOACs had an equal stroke/SE risk
as compared to VKAs in AF patients ≥75, ≥80, ≥85, and ≥90
years old (Avgil-Tsadok et al., 2016; Lai et al., 2018;
Giustozzi et al., 2019; Hohmann et al., 2019; Nishida et al.,
2019; Mitchell et al., 2019; Russo et al., 2019; Shinohara et al.,
2019; Alcusky et al., 2020). Some studies even described a
significantly lower stroke/SE (Deitelzweig et al., 2019; Kim
et al., 2019) and ischemic stroke risk (Mitchell et al., 2019;
Deitelzweig et al., 2019; Chao et al., 2020), as opposed to a
higher stroke/transient ischemic attack (TIA) risk in one small
Italian study (Poli et al., 2019) and a borderline increased
ischemic stroke/TIA risk for apixaban in another study due to
off-label underdosing (Alcusky et al., 2020). Mortality rates in
NOAC users were similar (Nishida et al., 2019; Mitchell et al.,
2019) to even significantly lower (Deitelzweig et al., 2019; Kim
et al., 2019; Poli et al., 2019; Russo et al., 2019; Alcusky et al.,
2020; Chao et al., 2020) as compared to warfarin. In terms of
safety, NOACs were associated with a similar (Giustozzi et al.,
2019; Mitchell et al., 2019; Nishida et al., 2019; Poli et al., 2019;
Russo et al., 2019; Chao et al., 2020) to lower (Kim et al., 2019;
Shinohara et al., 2019; Nishida et al., 2019; Chao et al., 2020;
Wong et al., 2020) major bleeding, a similar (Hohmann et al.,
2019; Kim et al., 2019) to significantly higher (Mitchell et al.,
2019; Wong et al., 2020) gastrointestinal bleeding and a lower
(Hohmann et al., 2019; Kim et al., 2019; Mitchell et al., 2019;
Chao et al., 2020; Wong et al., 2020) intracranial bleeding risk
(except for a similar risk in one study) (Russo et al., 2019) as
compared to VKAs in AF patients ≥75, ≥80, ≥85 and ≥90 years
old (Shinohara et al., 2019; Hohmann et al., 2019; Nishida et al.,
2019; Mitchell et al., 2019; Giustozzi et al., 2019; Russo et al.,
2019; Kim et al., 2019; Poli et al., 2019; Chao et al., 2020).
Interestingly, in AF patients ≥90 years old, the use of NOACs as
compared to no anticoagulation was associated with a
significantly lower risk for the composite effectiveness endpointFrontiers in Pharmacology | www.frontiersin.org 5(stroke/SE, pulmonary embolism and death), and a borderline
similar risk for major bleeding and intracranial bleeding
(Raposeiras-Roubıń et al., 2020). On the contrary, VKAs as
compared to no anticoagulation were associated with a similar risk
for the composite effectiveness endpoint, but a significantly higher
risk formajor bleeding and intracranial bleeding (Raposeiras-Roubıń
et al., 2020). This differential safety profile was also illustrated in a
Markov state transition model, demonstrating a lack of net clinical
benefit for warfarin as compared to no anticoagulation after the age
of 87, whereas only after the age of 92 for apixaban (Shah et al.,
2019). In other words, even the oldest AF patients appear to still
benefit from NOACs instead of discontinuing anticoagulation.
Moreover, in line with randomized studies, differences in safety
outcomes between NOACs were seen. Apixaban was associated
with a significantly lower major bleeding and intracranial bleeding
risk as compared to VKAs in ≥75 and ≥80 year old AF patients
(Deitelzweig et al., 2019; Hohmann et al., 2019; Alcusky et al.,
2020; Wong et al., 2020). Importantly, as the ARISTOTLE trial did
not provide data on the gastrointestinal bleeding risk of apixaban
in older AF patients, observational studies were reassuring,
illustrating a similar (Wong et al., 2020). to significantly lower
(Deitelzweig et al., 2019; Hohmann et al., 2019) gastro-intestinal
bleeding risk of apixaban as compared to VKAs in older AF
patients. Dabigatran was associated with a similar (Avgil-Tsadok
et al., 2016; Deitelzweig et al., 2019; Alcusky et al., 2020) to
significantly lower (Wong et al., 2020) major bleeding risk, a
similar (Lai et al., 2018; Deitelzweig et al., 2019; Hohmann et al.,
2019; Wong et al., 2020) to a significantly higher (Avgil-Tsadok
et al., 2016) gastrointestinal bleeding risk, and a significantly lower
(Avgil-Tsadok et al., 2016; Lai et al., 2018; Deitelzweig et al., 2019;
Wong et al., 2020) intracranial bleeding risk as compared to
warfarin in ≥75 in ≥75, ≥80 and ≥85 year old, ≥80 in ≥75, ≥80
and ≥85 year old, and ≥85-year-old AF patients (Avgil-Tsadok
et al., 2016; Lai et al., 2018; Deitelzweig et al., 2019; Hohmann
et al., 2019; Alcusky et al., 2020; Wong et al., 2020). On the
contrary, rivaroxaban was associated with a similar (Alcusky et al.,
2020) to significantly higher (Deitelzweig et al., 2019; Wong et al.,
2020) major bleeding risk, a similar (Lai et al., 2018) to
significantly higher (Deitelzweig et al., 2019; Hohmann et al.,
2019; Wong et al., 2020) gastrointestinal bleeding risk, and a
similar (Lai et al., 2018) to significantly lower (Deitelzweig et al.,
2019; Wong et al., 2020) intracranial bleeding risk as compared to
warfarin in ≥75 in ≤75, ≤80 and ≤85 year old, ≥80 in ≤75, ≤80 and
≤85 year old, and ≥85 in ≤75, ≤80 and ≤85 year old year-old AF
patients (Lai et al., 2018; Deitelzweig et al., 2019; Hohmann et al.,
2019; Alcusky et al., 2020; Wong et al., 2020). In a head-to-head
comparison between NOACs in AF patients ≥80 years, apixaban
was associated with a significantly lower risk of stroke/SE, major
bleeding, gastrointestinal bleeding and mortality as compared to
dabigatran and rivaroxaban, and even a significantly lower risk of
intracranial bleeding as compared to rivaroxaban (Deitelzweig
et al., 2019).
In conclusion, observational studies have illustrated the non-
inferior to superior effectiveness and safety profile of NOACs as
compared to VKAs in older AF patients, with most reassuring
data on apixaban. Importantly, even in the oldest AF patientsSeptember 2020 | Volume 11 | Article 583311
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discontinuation (Raposeiras-Roubıń et al., 2020).Meta-Analysis
After pooling the results of 6 post hoc analyses of RCTs and 6
observational studies in a meta-analysis, a significantly lower
stroke/SE and all-cause mortality risk of NOACs versus VKAs in
AF patients ≥75 years old was observed (HR 0.83, 95%CI [0.74-
0.94], I² 26.1% for stroke/SE; HR 0.77, 95%CI [0.65-0.92], I²
91.7% for mortality) (Figures 2 and 3). The considerable
heterogeneity noted for mortality outcomes may be due to
heterogeneous mortality results in two observational studies
(Nishida et al., 2019; Chao et al., 2020). When performing a
sensitivity analysis excluding these two studies, a significantly
lower all-cause mortality risk was still present and heterogeneity
was low (HR 0.79, 95%CI [0.73-0.86], I² 34.7%, eFigure 1).
Major bleeding risks were similar between NOACs and VKAs
(HR 0.93, 95%CI [0.86–1.01]), although substantial heterogeneity
was present (I² 84.6%), probably due to differential safety profiles
of the different types of NOACs used in older AF patients asFrontiers in Pharmacology | www.frontiersin.org 6discussed above (Figure 4). Indeed, when performing a sensitivity
analysis specifically comparing dabigatran and rivaroxaban to
VKAs, major bleeding risks were similar (HR 1.00, 95%CI
[0.92–1.09]) with lower but still substantial heterogeneity detected
(I² 76.8%) (eFigure 2A), although driven by heterogeneous results
from observational studies (I² 0.00% for results from RCTs, I² 82.6%
for results from observational studies) (eFigures 2B, C). When
specifically comparing apixaban and edoxaban to VKAs, major
bleeding risks were significantly lower (HR 0.77, 95%CI [0.65–0.91],
I² 70.9%) (eFigure 2D).
Furthermore, a significantly lower intracranial bleeding (HR
0.58, 95%CI [0.50–0.67], I² 63.1%) and a borderline similar
gastrointestinal bleeding risk (HR 1.17, 95%CI [0.99–1.38], I²
91.5%) were observed for NOACs as compared to VKAs (Figures
5 and 6). In a sensitivity analysis specifically comparing results
from dabigatran, rivaroxaban, and edoxaban to VKAs, a
significantly higher gastrointestinal bleeding risk (HR 1.28, 95%
CI [1.13–1.46], I² 82.6%) was demonstrated (eFigure 3A), with
substantial heterogeneity driven by dabigatran results (I² 81.9%
for dabigatran, I² 0.00% for rivaroxaban, not performed for edoxaban
as only one study was available) (eFigures 3B, C). However, whenFIGURE 2 | Forest plot of the risk of stroke or systemic embolism of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, apixaban 5 mg
(standard dose) and 2.5 mg (reduced dose); CI, confidence interval; Dabi 150, dabigatran 150 mg (standard dose); Dabi 110, dabigatran 110 mg (reduced dose);
Edo 60/30, edoxaban 60 mg (standard dose) and 30 mg (reduced dose); HR, hazard ratio; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized
controlled trial (post hoc analysis); RE model, random effects model; Riva, rivaroxaban; Riva 20/15, rivaroxaban 20 mg (standard dose) and 15 mg (reduced dose);
Riva 15/10, rivaroxaban 15 mg (standard dose) and 10 mg (reduced dose); Stroke/SE, stroke/systemic embolism; VKA, vitamin K antagonist.FIGURE 3 | Forest plot of the risk of all-cause mortality of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, apixaban 5 mg (standard
dose) and 2.5 mg (reduced dose); CI, confidence interval; Dabi 150, dabigatran 150 mg (standard dose); Dabi 110, dabigatran 110 mg (reduced dose); Death, all-
cause mortality; HR, hazard ratio; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized controlled trial (post hoc analysis); RE model, random effects
model; Riva, rivaroxaban; Riva 20/15, rivaroxaban 20 mg (standard dose) and 15 mg (reduced dose); VKA, vitamin K antagonist.September 2020 | Volume 11 | Article 583311
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(HR 0.78, 95%CI [0.54–1.13], I² 86.0%) was observed (eFigure 3D).
Moreover, in a subgroup analysis, results from observational
studies investigating very old AF patients (≥80, ≥85, or ≥90 years
old) were additionally included in the meta-analyses on the
effectiveness and safety outcomes of interest. Seven additional
observational cohort studies were included (four including AF
patients ≥80 years old (Deitelzweig et al., 2019; Kim et al., 2019;
Russo et al., 2019; Shinohara et al., 2019), two including AF
patients ≥85 years old (Lai et al., 2018; Poli et al., 2019), and one
including AF patients ≥90 years old) (Giustozzi et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 7Similar trends were observed, although the major bleeding risk
was significantly lower for NOACs as compared to VKAs in AF
patients ≥75, ≥80, ≥85, or ≥90 years old (HR 0.92, 95%CI [0.84-
0.998], I² 89.1%) (eFigures 4A–E).
No publication bias was suspected based on visual inspection
of funnel plots (eFigures 5A–E), except for mortality outcomes,
but this was probably due to considerable heterogeneity in study
results. Indeed, after excluding the two most heterogeneous
observational studies (Nishida et al., 2019; Chao et al., 2020) in
the abovementioned sensitivity analysis, publication bias was no
longer suspected (eFigure 5F).FIGURE 4 | Forest plot of the risk of major bleeding of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, apixaban 5 mg (standard
dose) and 2.5 mg (reduced dose); CI, confidence interval; Dabi 150, dabigatran 150 mg (standard dose); Dabi 110, dabigatran 110 mg (reduced dose); Edo 60/30,
edoxaban 60 mg (standard dose) and 30 mg (reduced dose); HR, hazard ratio; MB, major bleeding; NOAC, non-vitamin K antagonist oral anticoagulant; RCT,
randomized controlled trial (post hoc analysis); RE model, random effects model; Riva, rivaroxaban; Riva 20/15, rivaroxaban 20 mg (standard dose) and 15 mg
(reduced dose); Riva 15/10, rivaroxaban 15 mg (standard dose) and 10 mg (reduced dose); VKA, vitamin K antagonist.FIGURE 5 | Forest plot of the risk of intracranial bleeding of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, apixaban 5 mg
(standard dose) and 2.5 mg (reduced dose); CI, confidence interval; Dabi 150, dabigatran 150 mg (standard dose); Dabi 110, dabigatran 110 mg (reduced dose);
Edo 60/30, edoxaban 60 mg (standard dose) and 30 mg (reduced dose); HR, hazard ratio; ICH, intracranial bleeding; NOAC, non-vitamin K antagonist oral
anticoagulant; RCT, randomized controlled trial (post hoc analysis); RE model, random effects model; Riva, rivaroxaban; Riva 20/15, rivaroxaban 20 mg (standard
dose) and 15 mg (reduced dose); VKA, vitamin K antagonist.September 2020 | Volume 11 | Article 583311
Grymonprez et al. Anticoagulants in Older AF PatientsIn conclusion, NOAC use in AF patients ≥75 years old was
associated with a superior effectiveness and a non-inferior safety
profile as compared to VKAs in our meta-analysis based on
randomized and observational studies, which is in line with the
abovementioned RCT-based meta-analyses in older AF patients.
Multimorbidity
Unfortunately, studies investigating the impact of multimorbidity
based on the number of baseline comorbidities, are limited, as
only one study has been published so far (eTable 3). In this post
hoc analysis of the ARISTOTLE trial, apixaban use in AF patients
with moderate multimorbidity (3–5 comorbidities) was associated
with a significantly lower stroke/SE and major bleeding risk, and a
similar mortality risk as compared to warfarin, whereas in highly
multimorbid AF patients (≥6 comorbidities), all outcome risks
were similar (Alexander et al., 2019). More studies investigating
the impact of multimorbidity based on the absolute number of
baseline comorbidities are needed, although these preliminary
results illustrate the preserved efficacy and safety of apixaban, even
in patients with high multimorbidity.
A high clinical risk score, such as a high CHADS2, CHA2DS2-
VASc, or HAS-BLED score, can also be used as a proxy to
identify patients with multimorbidity, although comorbidities
not included in these risk scores are not acknowledged. Several
randomized and observational studies have reported outcome
rates of NOACs versus VKAs in AF patients with a high clinical
risk score, illustrating comparable results as seen in the overall
pivotal phase III RCTs (Connolly et al., 2009; Granger et al.,
2011; Patel et al., 2011; Giugliano et al., 2013) and studies on
increased age, namely the superior efficacy of apixaban and
standard dose dabigatran, the (mostly) superior safety of
apixaban, non-inferior safety of dabigatran and edoxaban, and
non-inferior (in randomized studies) to inferior (in observational
studies) safety of rivaroxaban as compared to warfarin (eTable
3). Indeed, significantly lower stroke/SE, major bleeding and
intracranial bleeding risks, and a similar mortality risk wereFrontiers in Pharmacology | www.frontiersin.org 8observed for apixaban-treated patients with a CHADS2 or
CHA2DS2-VASc score of ≥3 as compared to warfarin in a post
hoc analysis of the ARISTOTLE trial (Granger et al., 2011; Lopes
et al., 2012). In the RE-LY trial, dabigatran use in AF patients
with a CHADS2 score of ≥3 was associated with a similar (110
mg) to significantly lower (150 mg) stroke/SE risk, a similar
major bleeding risk (both doses), a significantly lower
intracranial bleeding risk (both doses) and a similar mortality
risk (both doses) as compared to warfarin (Connolly et al., 2009;
Oldgren et al., 2011). Likewise, non-inferior stroke/SE and major
bleeding risks in AF patients with a CHADS2 score of ≥3 were
observed in the ROCKET AF trial (Patel et al., 2011) and J-
ROCKET AF trial (Hori et al., 2014) for rivaroxaban, and in the
ENGAGE AF-TIMI 48 trial (Giugliano et al., 2013) for edoxaban.
In line with these randomized studies, four observational
cohort studies also examined the impact of multimorbidity based
on high CHA2DS2-VASc (4–5, ≥6) (Mentias et al., 2018;
Hernandez et al., 2018), HAS-BLED (≥4) (Wong et al., 2020),
Gagne comorbidity (3–4, ≥5) (Mentias et al., 2018), and/or
Charlson Comorbidity Index scores (≥4) (Hohmann et al.,
2019). In AF patients with multimorbidity, NOAC use was
associated with similar (Mentias et al., 2018; Hohmann et al.,
2019) to significantly lower (Hernandez et al., 2018) stroke/SE
and mortality risks, and significantly lower (Hohmann et al.,
2019; Wong et al., 2020) intracranial bleeding risks as compared
to warfarin (Hernandez et al., 2018; Mentias et al., 2018;
Hohmann et al., 2019; Wong et al., 2020). On safety outcomes,
both apixaban and dabigatran were associated with similar to
significantly lower major bleeding and gastrointestinal bleeding
risks compared to warfarin, as opposed to similar to significantly
higher major bleeding and gastrointestinal bleeding risks for
rivaroxaban across studies (Mentias et al., 2018; Hernandez et al.,
2018; Hohmann et al., 2019; Wong et al., 2020).
In conclusion, despite at least non-inferior effectiveness
outcomes, these observational studies highlight the potential
worse safety profile of rivaroxaban as opposed to non-inferiorFIGURE 6 | Forest plot of the risk of gastrointestinal bleeding of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, apixaban 5 mg
(standard dose) and 2.5 mg (reduced dose); CI, confidence interval; Dabi 150, dabigatran 150 mg (standard dose); Dabi 110, dabigatran 110 mg (reduced dose);
Edo 60/30, edoxaban 60 mg (standard dose) and 30 mg (reduced dose); GIB, gastrointestinal bleeding; HR, hazard ratio; NOAC, non-vitamin K antagonist oral
anticoagulant; RCT, randomized controlled trial (post hoc analysis); RE model, random effects model; Riva, rivaroxaban; Riva 20/15, rivaroxaban 20 mg (standard
dose) and 15 mg (reduced dose); VKA, vitamin K antagonist.September 2020 | Volume 11 | Article 583311
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patients with multimorbidity. These results are in line with the
abovementioned results in older AF patients, although safety
results of dabigatran appeared to be better in AF patients with
multimorbidity due to similar to significantly lower gastrointestinal
bleeding risks in observational studies.Polypharmacy
Post hoc analyses of two phase III RCTs (the ARISTOTLE
(Jaspers Focks et al., 2016) and ROCKET AF trial (Piccini et al.,
2016)) have been performed on the impact of polypharmacy,
illustrating the at least equal efficacy of apixaban and rivaroxaban,
non-inferior to superior safety of apixaban, and non-inferior to
inferior safety of rivaroxaban as compared to warfarin (eTable 4).
Indeed, similar stroke/SE and mortality risks were observed for
apixaban- and rivaroxaban- versus warfarin-treated AF patients
with polypharmacy (Jaspers Focks et al., 2016; Piccini et al., 2016).
Apixaban use in patients with 6–8 and ≥9 drugs was associated
with a significantly lower intracranial bleeding and similar
gastrointestinal bleeding risk as compared to warfarin (Jaspers
Focks et al., 2016), whereas rivaroxaban use in patients with 5–9
and ≥10 drugs was associated with a similar intracranial bleeding
risk (no report on gastrointestinal bleeding) (Piccini et al., 2016).
Intriguingly, a significant interaction between the number of
comedication use and both apixaban and rivaroxaban was
present for major bleeding (Jaspers Focks et al., 2016; Piccini
et al., 2016). For apixaban, the safety benefit was attenuated in AF
patients with the highest number of concomitant medications, as a
significantly lower major bleeding risk was observed in patients
with 6–8 drugs, whereas an equal risk in patients with ≥9 drugs
(Jaspers Focks et al., 2016). For rivaroxaban, a significantly higher
major bleeding risk was observed in patients with 5–9 drugs as
compared to warfarin, whereas a similar risk in patients with ≥10
drugs (Piccini et al., 2016).
Pooling the results of both RCTs, two meta-analyses
illustrated that NOACs were associated with a superior efficacy
(significantly lower stroke/SE and all-cause mortality risk) and
non-inferior safety (similar major bleeding risk) in AF patients
with polypharmacy (≥5 drugs) as compared to warfarin, which is
in line with results of our meta-analysis on increased age (Harskamp
et al., 2019; Kim et al., 2019).
Furthermore, two observational cohort studies on polypharmacy
(≥7 drugs (Hohmann et al., 2019) and ≥5 to ≥10 drugs (Martinez
et al., 2019)) illustrated results in line with the abovementioned
randomized studies and provided limited reassuring data on
dabigatran use in patients with polypharmacy. Similar (Hohmann
et al., 2019) to significantly lower (Martinez et al., 2019) stroke/SE
and significantly lower (Hohmann et al., 2019) intracranial bleeding
risks were observed for NOACs as compared to VKAs in these
studies. In one observational study, apixaban was associated with a
significantly lower gastrointestinal bleeding and similar other major
bleeding risk, dabigatran with a similar gastrointestinal bleeding and
lower other major bleeding risk, whereas rivaroxaban with a
significantly higher gastrointestinal bleeding and similar other
major bleeding risk as compared to phenprocoumon (Hohmann
et al., 2019). However, the other observational study, thoughFrontiers in Pharmacology | www.frontiersin.org 9industry-sponsored, observed similar major bleeding risks with
rivaroxaban as compared to warfarin in patients with ≥5 and ≥10
drug used (Martinez et al., 2019).
Overall, results on the impact of polypharmacy were consistent
as observed in AF patients with multimorbidity, highlighting the
preserved effectiveness of NOACs, the non-inferior to superior
safety of apixaban and dabigatran, and the opposing non-inferior
to inferior safety of rivaroxaban. However, as both randomized
and observational data on apixaban use in patients with
polypharmacy was most reassuring, apixaban use also appears
to be the first choice in patients with polypharmacy, as seen in
older AF patients. Nonetheless, the attenuated safety benefit of
apixaban in patients with the highest number of concomitant
medications should warrant caution and close monitoring.High Falling Risk
A high falling risk or recent fall does not automatically
contraindicate OAC use. In a Markov decision analytic model
using data on stroke and major bleeding rates in both non-
anticoagulated and VKA-treated AF patients ≥65 years old with
or without falls, the role for continuing instead of omitting OACs
was examined (Man-Son-Hing et al., 1999). Weighing the
increased risk for fall-related intracranial haemorrhage against
the substantial reduction in ischemic stroke risk among warfarin-
treated AF patients as compared to non-anticoagulated patients,
a person would have to fall about 295 times in 1 year for warfarin
not to be the preferred therapy (Man-Son-Hing et al., 1999). In
other words, AF patients at high risk of falling still appear to
benefit from anticoagulation despite the associated risk for
intracranial haemorrhage. Therefore, it is of importance to
evaluate potential differences in outcomes between individual
OACs, especially regarding intracranial haemorrhage as the most
feared fall-related outcome. However, only two secondary
analyses of phase III RCTs studies specifically assessed the
impact of high falling risk on NOAC efficacy and safety,
namely the ARISTOTLE (Rao et al., 2018) and ENGAGE AF-
TIMI 48 trial (Steffel et al., 2016), though these were largely
underpowered (eTable 5). In apixaban-treated AF patients with
≥1 prior fall in the last year, the risk of intracranial bleeding was
significantly lower as compared to warfarin, whereas the risks of
stroke/SE, major bleeding and mortality were similar (Rao et al.,
2018). Likewise, a significantly lower intracranial bleeding risk,
and similar stroke/SE, major bleeding, gastrointestinal bleeding
and mortality risks were observed for edoxaban users at high risk
of falling as compared to warfarin (Steffel et al., 2016). Besides
lack of subgroup analyses of the RE-LY (Connolly et al., 2009)
and ROCKET AF trial (Patel et al., 2011), to the best of our
knowledge, no large observational studies have been performed so
far specifically comparing the effectiveness and safety of individual
NOACs in AF patients at high falling risk. This emphasizes an
urgent need for more research on the topic to help guide
physicians in their OAC choice for AF patients at high falling risk.
While awaiting more results, the preserved efficacy and safety
outcomes of apixaban and edoxaban may warrant their use in AF
patients prone to fall, especially because of the significantly lower
intracranial bleeding risk.September 2020 | Volume 11 | Article 583311
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Unfortunately, as the four pivotal phase III RCTs did not
specifically include or investigate frail AF patients, especially
since patients with an estimated life expectancy of <1–2 years or
less than the expected trial duration were excluded (Connolly
et al., 2009; Lopes et al., 2010; Ruff et al., 2010; Granger et al.,
2011; Patel et al., 2011; Giugliano et al., 2013), randomized data is
lacking on the impact of frailty on the efficacy and safety of
NOACs in AF. Luckily, limited yet useful observational data is
emerging on this clinically relevant topic, highlighting
comparable results as seen in studies on increased age, namely
the similar effectiveness of all NOACs and the most favourable
safety profile of apixaban in contrast to the least favourable
profile of rivaroxaban (eTable 6).
Indeed, in a retrospective cohort study including frail AF patients
using the Johns Hopkins Claims-based Frailty Indicator (Segal et al.,
2017), NOAC use was associated with a similar stroke/SE and
gastrointestinal bleeding risk, and a significantly lower intracranial
and other major bleeding risk as compared to phenprocoumon
(Hohmann et al., 2019). Importantly, as seen in studies investigating
older AF patients, differential safety outcomes between individual
NOACs were noted in frail patients. Apixaban was associated with a
significantly lower gastro-intestinal bleeding risk, dabigatran with a
similar risk, whereas rivaroxaban with a significantly higher risk as
compared to phenprocoumon. Moreover, another retrospective
cohort study identified frail AF patients using the same Johns
Hopkins Claims-based Frailty Indicator (Segal et al., 2017), and
observed similar stroke/SE risk for NOACs as compared to warfarin
(Martinez et al., 2018). Apixaban was associated with a significantly
lower major bleeding but similar intracranial bleeding risk (though
the number of events was very low), whereas dabigatran and
rivaroxaban with a similar major bleeding but significantly lower
intracranial bleeding risk. Additionally, apixaban and dabigatran
were associated with a similar gastrointestinal bleeding risk, but
rivaroxaban with a higher risk.
In conclusion, although evidence is limited, these studies
illustrate that the effectiveness and safety of NOACs appear to
be consistent in frail patients, as observed in older AF patients,
with apixaban having the most favourable benefit-risk profile.
Nonetheless, more studies are needed on the role of individual
NOACs in frail AF patients, especially of edoxaban.Dementia
Data on the effectiveness and safety of OACs, especially NOACs,
in AF patients with dementia are limited. Unfortunately, phase
III RCTs did not include AF patients with dementia due to
inability to comply with study-related procedures or to give an
informed consent, so no randomized data in this population is
available (Connolly et al., 2009; Lopes et al., 2010; Ruff et al.,
2010; Granger et al., 2011; Patel et al., 2011; Giugliano et al.,
2013; Fanning et al., 2020). However, some observational studies
have provided exploratory data on this topic, illustrating the
benefit of OAC continuation over discontinuation, as seen in the
oldest AF patients ≥90 years old (eTable 7). Indeed, warfarin-
treated AF patients with dementia in the Swedish Dementia
Registry and Veterans Affairs database had significantly lowerFrontiers in Pharmacology | www.frontiersin.org 10thromboembolic and mortality risks as compared to non-
anticoagulated AF patients with dementia, without significantly
increasing major bleeding or non-traumatic intracranial bleeding
risks (Orkaby et al., 2017; Subic et al., 2018).
Regarding the comparative effectiveness and safety of NOACs
versus VKAs, only one retrospective cohort study provided some
preliminary data, illustrating similar stroke/SE and other major
bleeding risks, a significantly lower intracranial bleeding risk,
and significantly higher gastrointestinal bleeding and mortality
risks for NOACs versus warfarin in AF patients with dementia
(Fanning et al., 2020). However, analyses were not time-
dependent, and results may have been influenced by selective
prescribing and pooling of NOAC data, necessitating cautious
interpretation of these results.
In conclusion, these limited results are comparable to those
observed in AF patients ≥90 years old, namely a potential
beneficial role for OAC continuation in AF patients with
dementia instead of stopping the OAC (Orkaby et al., 2017;
Subic et al., 2018). In other words, dementia in itself should not
be viewed as a general contraindication for OACs. However, the
severity of dementia should also be assessed when evaluating the
necessity for OAC continuation. Moreover, it is still unclear what
type of OAC should be preferred in these patients as strong
evidence is lacking. This highlights the urgent need for more
studies investigating the benefit-risk profile of NOACs in AF
patients with cognitive impairment and dementia.DISCUSSION
General Trends
The use of OACs in vulnerable geriatric AF patients is a matter of
concern for physicians, faced with the challenge of outweighing
the benefits of stroke reduction against the risk of bleeding.
Vulnerable older AF patients are frequently characterized by
multimorbidity, polypharmacy, increased falling risk, frailty and
dementia (Jaspers Focks et al., 2016; Piccini et al., 2016; Steffel
et al., 2016; Martinez et al., 2018; Rao et al., 2018; Alexander
et al., 2019). Consequently, OACs tend to be inappropriately
underdosed or discontinued in these patients subgroups
(Viscogliosi et al., 2017; Oqab et al., 2018; Madhavan et al.,
2019; Proietti et al., 2019; Besford et al., 2020; Kapoor et al., 2020;
Sanghai et al., 2020). However, even in AF patients ≥90 years old
(Raposeiras-Roubıń et al., 2020), at high risk of falling (Man-
Son-Hing et al., 1999) or with dementia (Orkaby et al., 2017;
Subic et al., 2018), OAC continuation was still beneficial
compared to omitting the OAC. Therefore, very high age,
recent fall or cognitive impairment should not be considered
as strict contraindications for OAC use, provided that an
individual benefit-risk assessment is performed.
Even though the pivotal phase III RCTs were not designed and
powered to investigate OAC use in geriatric patients, the available
randomized evidence and also post-surveillance observational
studies suggest that the effectiveness and safety of NOAC as
compared to warfarin remain consistent, with apixaban
exhibiting the most favourable benefit-risk profile of all OACsSeptember 2020 | Volume 11 | Article 583311
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results). Our meta-analysis including results of 6 post hoc analyses
of RCTs and 6 observational studies, highlighted superior results
on stroke/SE, mortality and intracranial bleeding risks, whereas
non-inferior results on major bleeding and gastrointestinal
bleeding risks for NOACs as compared to VKAs in AF patients
≥75 years old. Even after additionally including seven observational
studies investigating patients ≥80, ≥85, or ≥90 years old, consistent
results were demonstrated, though the major bleeding risk was
significantly lower for NOACs as compared to VKAs. However,
safety differences between individual NOACs were identified, as
increasing age above 75 years significantly interacted with the safety
of dabigatran and rivaroxaban, illustrating non-inferior to inferior
safety results in older AF patients, especially due to a higher
gastrointestinal bleeding risk of both NOACs and a similar
intracranial bleeding risk of rivaroxaban as compared to warfarin
(Eikelboom et al., 2011; Halperin et al., 2014; Lin et al., 2015; Avgil-
Tsadok et al., 2016; Lai et al., 2018; Deitelzweig et al., 2019;
Hohmann et al., 2019; Wong et al., 2020). On the contrary, the
superior safety profile of apixaban was preserved in older AF
patients, with a significantly lower major, intracranial and
gastrointestinal bleeding risk as compared to warfarin (Halvorsen
et al., 2014; Lin et al., 2015; Deitelzweig et al., 2019; Hohmann et al.,
2019; Alcusky et al., 2020; Wong et al., 2020). Likewise, edoxaban
was associated with a similar (standard dose) to significantly lower
(reduced dose) major bleeding risk and a lower intracranial
bleeding risk as compared to warfarin, although higher
gastrointestinal bleedings risks were also noted (Kato et al., 2016).
Similarly, in AF patients with multimorbidity or polypharmacy,
apixaban (Granger et al., 2011; Jaspers Focks et al., 2016; Alexander
et al., 2019; Harskamp et al., 2019; Hohmann et al., 2019) was
associated with the most favourable effectiveness and safety profile
of all NOACs, followed by edoxaban (Giugliano et al., 2013),
dabigatran (Connolly et al., 2009; Oldgren et al., 2011;
Hernandez et al., 2018; Mentias et al., 2018; Hohmann et al.,
2019; Wong et al., 2020), and rivaroxaban (Piccini et al., 2016;
Hernandez et al., 2018; Mentias et al., 2018; Harskamp et al., 2019;
Hohmann et al., 2019; Martinez et al., 2019; Wong et al., 2020).
In AF patients at high risk of falling, with frailty or dementia,
considerably less evidence was available, mostly due to exclusion
of these subjects in RCTs, which complicates recommendations
for clinical practice. Therefore, more studies are necessary in
these patient subgroups. Notwithstanding, apixaban’s preferential
benefit-risk profile was maintained in patients prone to fall and
with frailty, illustrating a similar effectiveness and non-inferior to
superior safety as compared to warfarin (Rao et al., 2018;
Hohmann et al., 2019). The preserved significantly lower
intracranial bleeding risk is of particular importance in high-risk
fallers (Rao et al., 2018). Furthermore, dabigatran in frail patients
(Hohmann et al., 2019) and edoxaban in patients prone to fall
(Steffel et al., 2016) illustrated similar benefit-risk profiles as
compared to warfarin, whereas rivaroxaban showed a non-
inferior to inferior safety profile in frail patients (Martinez et al.,
2018; Hohmann et al., 2019). As only one study examined the
effectiveness and safety of NOACs as compared to warfarin in AF
patients with dementia, illustrating a similar stroke/SE and majorFrontiers in Pharmacology | www.frontiersin.org 11bleeding risk, as opposed to a higher gastrointestinal bleeding and
mortality risk, there is an urgent need for more research on the
effectiveness and safety of individual NOACs in dement AF
patients (Fanning et al., 2020).Pathophysiological Mechanisms
Several mechanisms for differential safety results of individual
NOACs in older AF patients have been proposed. As the decline
in renal function gradually progresses with age and the metabolism
of dabigatran is the most dependent on renal clearance of all
NOACs (80% renal clearance as opposed to only 27% for
apixaban) (Steffel et al., 2018), the subsequent higher plasma
concentrations of fixed-dose dabigatran may partially explain the
increased bleeding risk in older patients (Eikelboom et al., 2011;
Lauw et al., 2017). Moreover, as the bioavailability of dabigatran
after oral ingestion is the lowest of all NOACs (only 3–7%) (Steffel
et al., 2018), intra-intestinal metabolism of the prodrug dabigatran
etexilate to the active drug during transit could lead to gradually
higher concentrations and local bleeding of the gastrointestinal tract
by direct drug exposure at bleeding sensitive foci such as
diverticulosis, angiodysplasia and colorectal polyposis (Eikelboom
et al., 2011). Since warfarin has a high bioavailability and its
anticoagulant mechanism of action depends on hepatic enzymes
(vitamin K-dependent g-carboxylation of coagulation factors II, VII,
IX, and X) resulting in less direct drug exposure at intra-intestinal
bleeding sensitive foci, this could explain the higher gastrointestinal
bleeding risk of dabigatran at higher age as compared to warfarin
(Eikelboom et al., 2011). Although rivaroxaban has a very high
bioavailability (80%–100% if taken together with food), intestinal
clearance through P-glycoprotein (P-gp)-dependent biliary and
intestinal excretion is substantial, as rivaroxaban’s clearance is
65% non-renal, 47% of which through intestinal excretion (Steffel
et al., 2018). This may lead to high intra-intestinal concentrations of
rivaroxaban, locally affecting diseased mucosa and resulting in
higher gastrointestinal bleeding risks in older patients as
compared to warfarin (Eikelboom et al., 2011). Similarly, the
higher gastrointestinal bleeding risk of edoxaban in older patients
(Kato et al., 2016) may be due to its 62% bioavailability and 46%
intestinal clearance (Steffel et al., 2018). However, as the
bioavailability of apixaban is also 50% and the intestinal clearance
is similar (48%) (Steffel et al., 2018), this pathophysiological
mechanism cannot explain why the gastrointestinal bleeding risk
is less pronounced in apixaban. Other age-related pharmacokinetic
and -dynamic changes may also play a role, such as the decreased
hepatic function with reduced drug clearance (relevant for apixaban
and rivaroxaban, being +/- 18% and 25% respectively hepatically
metabolized (Steffel et al., 2018)), changes in plasma protein binding
due to decreasing albumin levels (most important for rivaroxaban
and apixaban, being 95% and 87% plasma protein bound
respectively (Steffel et al., 2018)) and the prolonged elimination
half-life in older patients (11–13 h for rivaroxaban versus 5–9 h in
younger patients) (Grandison and Boudinot, 2000; McLean and Le
Couteur, 2004; Mueck et al., 2011; Steffel et al., 2018).
Potential mechanisms on the reduced risk for intracranial
haemorrhage in NOACs as compared to VKAs have also beenSeptember 2020 | Volume 11 | Article 583311
Grymonprez et al. Anticoagulants in Older AF PatientsTABLE 1 | The effectiveness and safety of each NOAC as compared to vitamin K antagonists in atrial fibrillation patients at increased age (≥75 years old),
multimorbidity, polypharmacy, high falling risk, frailty, and baseline dementia.
DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN
≥75 YEARS OLD 150mg 110mg
Stroke/systemic embolism
(SE)
RCT ↘ = = ↘ =
Obs. = to ↘ = to ↘ = to ↘ NR
Major bleeding RCT = = = ↘ ↘
Obs. = to ↘ = to ↗ ↘ NR
Intracranial hemorrhage
(ICH)
RCT ↘ ↘ = ↘ ↘
Obs. ↘ = to ↘ ↘ NR
Gastrointestinal bleeding
(GIB)
RCT ↗ ↗ ↗ NR ↗
Obs. = to ↗ = to ↗ = to ↘ NR
Mortality RCT = = NR NR NR
Obs. ↘ = to ↘ ↘ NR
MULTIMORBIDITY‡ 150mg 110mg 3-5† ≥6†
Stroke/SE RCT
↘ = =
↘ =
=
↘‡
Obs. = to ↘ = to ↘ = to ↘ NR
Major bleeding RCT
= = =
↘ =
=
↘‡
Obs. = = to ↗ = NR
ICH RCT ↘ ↘ NR NR NR
Obs. = to ↘ = to ↘ = to ↘ NR
GIB RCT NR NR NR NR NR
Obs. = to ↘ ↗ = to ↘ NR
Mortality RCT = = NR = = NR
Obs. ↘ = to ↘ ↘ NR
POLYPHARMACY ≥5 drugs ≥10drugs >5 drugs ≥9 drugs
Stroke/SE RCT NR = = = NR
Obs. NR ↘ = NR NR
Major bleeding RCT NR ↗ = ↘ = NR
Obs. NR = = NR NR
ICH RCT NR = ↘ ↘ NR
Obs. NR NR NR NR
GIB RCT NR NR NR = = NR
Obs. = ↗ ↘ NR
Mortality RCT NR = = = NR
Obs. NR NR NR NR
HIGH FALLING RISK
Stroke/SE RCT NR NR = =
Major bleeding RCT NR NR = =
ICH RCT NR NR ↘ ↘
GIB RCT NR NR NR =
Mortality RCT NR NR = =
FRAILTY
Stroke/SE Obs. = = = NR
Major bleeding Obs. = = ↘ NR
ICH Obs. ↘ ↘ = to ↘ NR
GIB Obs. = ↗ = to ↘ NR
Mortality Obs. NR NR NR NR
DEMENTIAi NOACsi
Stroke/SE Obs. =
Major bleeding Obs. =
ICH Obs. ↘
GIB Obs. ↗
Mortality Obs. ↗Frontiers in Pharmacology | www.frontiersin.org 12 September 2020 | Vo= (yellow): non-inferior results (similar risk) when comparing NOAC to VKAs; ↘ (green): superior results (significantly lower risk) when comparing NOAC to VKAs; ↗ (red): inferior results (significantly
higher risk) when comparing NOAC to VKAs; = to ↘ (yellow-green): non-inferior to superior results, varying across studies; = to ↗ (yellow-red): non-inferior to inferior results, varying across studies.
†number of baseline comorbidities; ‡high clinical risk score (e.g. CHA2DS2-VASc score ≥3);
icareful interpretation of results necessary, as only one observational study provided preliminary (pooled) data.
GIB, gastrointestinal bleeding; ICH, intracranial bleeding; NR, not reported; Obs., longitudinal observational cohort study; RCT, (post hoc analysis of) randomized clinical trial; Stroke/SE,
stroke/systemic embolism.lume 11 | Article 583311
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NOACs is approximately 12 h, which is significantly shorter than
that of VKAs, early discontinuation in case of head trauma or
spontaneous bleeding might limit development and progression of
intracranial bleeding (Rao et al., 2018; Steffel et al., 2018).
Moreover, as NOACs only target factor IIa (dabigatran) or Xa
(rivaroxaban, apixaban and edoxaban), whereas VKAs target factor
II, VII, IX, and X, it has been proposed that the lack of impact on
factor VII by NOACs may help to decrease trauma-related
bleeding, especially intracranial haemorrhage (Eikelboom et al.,
2011; Rao et al., 2018). Factor VII is an important coagulation
factor of the extracellular pathway, initiating clot formulation
together with tissue factor (Eikelboom et al., 2011; Rao et al.,
2018). Tissue factor is found in high concentrations in the brain,
where it may provide supplemental haemostatic protection
together with factor VII in case of trauma (Mackman, 2009;
Eikelboom et al., 2011). Indeed, in an exploratory case series
analysis in factor VII deficient AF patients, severe bleeding risk
was increased in warfarin-treated patients, whereas no haemorrhagic
events occurred in dabigatran-treated patients, providing preliminary
data on the importance of factor VII in major bleeding events (Arletti
et al., 2019). However, larger studies are needed to confirm
these findings.
The risk of stroke in older AF patients varies across studies,
documenting similar to significantly lower stroke/SE risks for
NOACs as compared to warfarin. This may be due to the VKA-
associated increase in vascular calcification (Weijs et al., 2011; Deng
et al., 2020; Millenaar et al., 2020). However, it should be mentioned
that not all stroke events in AF patients are necessarily cardio-
embolic in origin, which may affect stroke incidence rates of
individual OACs in different studies by chance (Paciaroni et al.,
2019). For example, in the RENo study examining NOAC-treated
AF patients with an acute ischemic stroke, about 30% of patients
had a stroke due to causes other than cardio-embolism (e.g. small
vessel disease) (Paciaroni et al., 2019).
Another frequently proposed mechanism, increasing the risk
for adverse outcomes in older AF patients, are DDIs. The risk of
DDIs increases with the number of comorbidities and
comedication use (Jaspers Focks et al., 2016; Piccini et al.,
2016; Alexander et al., 2019; Harskamp et al., 2019). VKAs
have multiple common drug-drug and drug-food interactions,
requiring frequent dose adjustments due to the narrow
therapeutic window (Kirchhof et al., 2016; Piccini et al., 2016;
Steffel et al., 2018). NOACs have less DDIs, but these should not
be neglected (Steffel et al., 2018). Two types can be identified:
pharmacokinetic and pharmacodynamic DDIs. For NOACs, two
major pharmacokinetic interaction mechanisms are present.
First, all NOACs are a substrate of the P-gp efflux transporter,
which is mostly present in the gastrointestinal lumen, resulting in
gastrointestinal excretion of NOACs after absorption in the gut
(Leslie et al., 2005; Steffel et al., 2018; Kim et al., 2019; Washam
et al., 2019). Its presence in the liver contributes to hepatobiliary
drug excretion, while P-gp transporters located in proximal
tubules play a role in the active renal clearance of NOACs
(Leslie et al., 2005; Gnoth et al., 2011; Steffel et al., 2018; Kim
et al., 2019). Moreover, as P-gp is also expressed in capillaryFrontiers in Pharmacology | www.frontiersin.org 13endothelial cells making up the blood-brain barrier to prevent
passage of drugs into the brain, P-gp inhibition might slightly
increase NOAC concentrations in the brain and potentially
decrease the beneficial safety of NOACs on intracranial
bleeding risks (Leslie et al., 2005; Gnoth et al., 2011; Kim et al.,
2019). Second, apixaban and rivaroxaban are partially dependent
on hepatic clearance, mostly mediated through the cytochrome
P450 3A4 isoenzyme (CYP3A4) (Steffel et al., 2018; Washam
et al., 2019). On the contrary, CYP3A4-mediated hepatic
metabolism is not involved in the clearance of dabigatran and
only minimally (<4%) in edoxaban (Steffel et al., 2018).
Therefore, CYP3A4-mediated DDIs do not significantly affect
dabigatran and edoxaban plasma concentrations. P-gp and/or
CYP3A4 inhibitors (e.g. amiodarone, dronedarone, verapamil…)
can increase NOAC plasma concentration due to a decreased
gastrointestinal excretion and/or hepatic metabolism respectively,
resulting in an increased bleeding risk (Piccini et al., 2016; Steffel
et al., 2018; Kim et al., 2019; Washam et al., 2019). Similarly, P-gp
and/or CYP3A4 inducers may decrease plasma concentrations,
subsequently increasing thromboembolic risks (Steffel et al., 2018;
Washam et al., 2019). It should be noted that in all phase III RCTs,
the use of strong CYP3A4 and/or P-gp inhibitors and inducers
was prohibited, limiting the generalizability of the results to real-
life clinical practice (Connolly et al., 2009; Lopes et al., 2010; Ruff
et al., 2010; Granger et al., 2011; Patel et al., 2011; Giugliano et al.,
2013; Jaspers Focks et al., 2016). Common pharmacodynamically
interacting drugs are antiplatelets, NSAIDs, selective serotonin
reuptake inhibitors and corticosteroids, which may increase the
risk of bleeding (Steffel et al., 2018). Several studies have been
published on the impact of (strong) individual DDIs on NOAC
effectiveness and safety. However, the potential synergistic impact
of multiple weak-moderate DDIs in one patient may also
influence outcomes and should not be neglected, especially not
in patients with polypharmacy.
Nevertheless, the differential safety profiles of NOACs in older
AF patients cannot be fully explained by these mechanisms, so other
unidentified age-dependent pathophysiological mechanisms may
contribute as well.Strengths and Limitations of Available
Literature
The included RCTs have many strengths, such as the use of
rigorous methodologies, detailed protocols, pre-specified statistical
analyses and well-defined patient cohorts (Beyer-Westendorf
et al., 2016). However, RCTs are usually underpowered for
subgroups analyses and run too short for (long-term) safety
outcomes, do not take into account the complexity of real-world
clinical decision-making, and difficult-to-reach populations tend
to be underrepresented due to ethical and practical considerations
(Beyer-Westendorf et al., 2016; Maetens et al., 2016; Camm et al.,
2018). The included observational studies tackle these shortcoming
in part, including large vulnerable patient subgroups with long
follow-up in a real-world setting. However, when comparing
different studies in geriatric AF patients, several limitations were
present influencing the interpretability of results.September 2020 | Volume 11 | Article 583311
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most studies, which frequently resulted in pooling data of all
NOACs despite differential safety results. Some studies also
included OAC-experienced patients, which may lead to healthy
user bias (Giustozzi et al., 2019). Second, NOACs dosages
differed across studies. For example, rivaroxaban was used in
lower dosages in Japan than approved in Europe (15 and 10 mg
as standard and reduced dose respectively) (Hori et al., 2012;
Group JCSJW, 2014). Likewise, 75 mg twice daily is the approved
reduced dosage of dabigatran in the US (Pradaxa), whereas 110
mg twice daily in Europe (Steffel et al., 2018). Moreover,
differences in off-label NOAC over- or underdosing in
observational studies complicated the comparability of results
(Alcusky et al., 2020; Raposeiras-Roubıń et al., 2020). Third,
most results were compared to warfarin, but also other VKAs
such as phenprocoumon were sometimes used. Besides VKAs,
other studies used aspirin, no OAC or non-AF patients as
comparator arm, necessitating exclusion of these studies.
Fourth, outcomes varied notably, with studies investigating
ischemic stroke, overall stroke, stroke/TIA, stroke/SE, stroke/
TIA/SE or stroke/SE/myocardial infarction as effectiveness
outcome. Likewise, primary safety endpoints varied, from
location-specific bleeding, major bleeding, major or clinically
relevant non-major bleeding to any bleeding. These differential
outcomes made comparisons between studies difficult. Fifth,
many included observational studies were performed in an
Asian setting. However, results from Asian studies cannot
always be automatically generalized to other populations. For
example, Asian AF patients seem to have higher stroke rates
(especially haemorrhagic stroke) than Caucasian AF patients,
and are also more prone to warfarin-related major bleeding
events, especially intracranial bleeding (Hori et al., 2013; Chiang
et al., 2014; Chao et al., 2019). Japanese guidelines therefore
recommend a target INR of 1.6–2.6 in AF patients ≥70 years old
[instead of 2.0–3.0 in Western countries] (Hori et al., 2012;
Group JCSJW, 2014; Steffel et al., 2018). Moreover, the mean
TTR in warfarin-treated Asian patients tends to be lower than in
Caucasian patients (Chiang et al., 2014; Piccini et al., 2014; Chao
et al., 2019). Due to these underlying ethnic differences, NOACs
tend to have a better effectiveness and safety than VKAs in Asian
patients. Sixth, the classification of the geriatric patient
subgroups varied across studies. For example, the assessment
methods of frailty varied across studies, identifying frailty based
on a questionnaire (Gullón et al., 2019), clinical frailty score
(Shinohara et al., 2019) or a healthcare claims-based scoring
algorithm (Segal et al., 2017). Likewise, different definitions for
polypharmacy and multimorbidity were used, limiting the
comparability of results (Jaspers Focks et al., 2016; Piccini
et al., 2016). Lastly, differences in design and selection bias
may have also influenced results. For example, in the RE-LY
trial, no pre-specified dose reduction criteria for dabigatran were
defined, resulting in approximately similar numbers of
dabigatran 110 and 150 mg users in older AF patients, due to
randomization (Connolly et al., 2009; Eikelboom et al., 2011).
This potential inappropriate use of standard dose dabigatran
may have resulted in worse adverse outcomes in older AFFrontiers in Pharmacology | www.frontiersin.org 14patients. Moreover, selection bias due to differences in baseline
characteristics of the included trial population may have affected
safety results. Exemplary, the median CHADS2 score ranged
from 2.1 in the ARISTOTLE trial (Granger et al., 2011) to 3.5 in
the ROCKET AF trial (Patel et al., 2011), which may suggest
inclusion of healthier AF patients in the ARISTOTLE trial.
Similarly, only 13.9% of older subjects required a reduced dose
of apixaban in the ARISTOTLE trial (Halvorsen et al., 2014).
Importantly, when assessing the quality of studies using the
quality assessment tool ‘QUALSYST’ (Kmet et al., 2004), post hoc
analyses of the RE-LY (Eikelboom et al., 2011; Lauw et al., 2017)
and ARISTOTLE (Halvorsen et al., 2014) trial lacked the
comparison between the baseline characteristics of NOAC
versus VKA users in the subgroup of patients ≥75 years old,
since only overall characteristics of this subgroup were reported.
Included observational studies (Avgil-Tsadok et al., 2016;
Hohmann et al., 2019; Alcusky et al., 2020; Chao et al., 2020;
Wong et al., 2020) frequently lacked well defined outcomes
which are robust to measurement bias or were limited in their
controlling for important confounders.
Recommendation for Clinical Practice
Overall, across characteristics typical for vulnerable geriatric AF
patients, apixaban was consistently associated with the best
efficacy and safety profile and appears to be therefore preferred
in geriatric patients. Although edoxaban ranked second on safety
endpoints and third on efficacy outcomes in AF patients ≥75
years old (Deng et al., 2020), data are lacking on the impact of
other geriatric patient characteristics, limiting the generalizability
of the reassuring edoxaban results in older patients to all
multimorbid, frail AF patients with polypharmacy. Dabigatran
appears to have a more intermediate place in geriatric AF patients,
especially due to the frequently noted higher gastrointestinal
bleeding risks. Despite solid effectiveness results, rivaroxaban
was mostly associated with worse safety outcomes across
geriatric patient subgroups, due to similar intracranial and
higher gastrointestinal bleeding risks.
Besides continuing and appropriately dosing NOACs,
meticulous attention has to be addressed to recognizing and
tackling modifiable bleeding risk factors such as hypertension,
non-indicated NSAID or antiplatelet use, and excessive alcohol
consumption (Kirchhof et al., 2016; Steffel et al., 2018). Moreover,
prevention and management of falls using strength, balance and
gait training; walking aids; correction of environmental hazards
(e.g. loose carpets); and correction of footwear or structural
impairments of the feet, are essential in the general approach of
these geriatric patients, especially at high risk of falling (Avin et al.,
2015). Furthermore, therapy adherence in community-dwelling
AF patients, especially with cognitive impairment, should be
optimized, for example by using weekly tablet boxes,
electronically monitored medication dispensing systems or
administration by a home health nurse or family member
(Steffel et al., 2018). In addition, a thorough medication review
and switching or discontinuing unnecessary, interacting or
contraindicated comedication should be the cornerstone of
management of older AF patients, especially with polypharmacy,September 2020 | Volume 11 | Article 583311
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clinically relevant drug-drug interactions (DDIs). To identify
and address the presence of (multiple) DDIs, the 2018 European
Heart Rhythm Association (EHRA) guidelines have made a
practical guide on NOAC dosing in patients using interacting
drugs (Steffel et al., 2018). Lastly, an individual benefit-risk
assessment and shared decision making must always be the
cornerstone of clinical practice when deciding on whether a
vulnerable geriatric patient with AF should be anticoagulated or
not. Severe cases, such as patients suffering major non-traumatic
intracranial haemorrhage, highly repetitive falling due to
generalized epilepsy or severe multisystem atrophy, or severely
frail patients with limited life expectancy, should warrant OAC
discontinuation (Kirchhof et al., 2016). Performing a comprehensive
geriatric assessment (CGA) in hospitalized older patients with AF
may help guide clinicians in this individual benefit-risk assessment
(Ellis et al., 2011).
Research Gaps
Although a vast amount of evidence on the impact of increased
age on the efficacy and safety of OACs was present, data are
substantially lacking on the impact of most other geriatric patient
subgroup characteristics. This systematic review has identified
considerable research gaps on the impact of high falling risk,
frailty and especially baseline dementia on NOAC effectiveness
and safety. Moreover, more research on the impact of the
number of baseline comorbidities to identify multimorbidity,
as well as post-surveillance data on edoxaban in other than high
age geriatric subgroups are needed.CONCLUSION
Increased age, multimorbidity, polypharmacy, high falling risk,
frailty and dementia are no formal contraindications for
anticoagulation in geriatric AF patients, since the benefit-risk
profile of NOAC as compared to VKAs remained consistentlyFrontiers in Pharmacology | www.frontiersin.org 15favourable in these patient subgroups. Indeed, our meta-analysis
highlighted a superior effectiveness and non-inferior safety
profile of NOACs in AF patients ≥75 years old as compared to
VKAs. Instead of off-label underdosing or discontinuing OACs,
physicians should tackle modifiable bleeding risk factors,
optimize therapy adherence, initialize fall prevention, execute a
thorough medication review and perform an individualized
benefit-risk assessment with shared decision making in each
geriatric AF patient. Importantly, apixaban was consistently
associated with the most favourable benefit-risk profile across
subgroups and should therefore be preferred in geriatric AF
patients. However, regarding the impact of high falling risk,
frailty and baseline dementia, important research gaps were
identified, necessitating more research on these topics.AUTHOR CONTRIBUTIONS
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